GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Fiche publication
Date publication
juillet 2020
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SPAETH Dominique, Mme POZET Astrid
Tous les auteurs :
Selle F, Heudel PE, Hardy-Bessard AC, Pozet A, Meunier J, Gladieff L, Lotz JP, Provansal M, Augereau P, Berton D, Bonichon-Lamichhane N, Orfeuvre H, Pautier P, Kalbacher E, Tazi Y, Spaeth D
Lien Pubmed
Résumé
Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice.
Mots clés
Ovarian cancer, pegylated liposomal doxorubicin, platinum-sensitive, trabectedin
Référence
Anticancer Res.. 2020 Jul;40(7):3939-3945